Compare EVN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVN | DRUG |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 364.8M |
| IPO Year | N/A | N/A |
| Metric | EVN | DRUG |
|---|---|---|
| Price | $10.81 | $90.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $104.00 |
| AVG Volume (30 Days) | 101.2K | ★ 243.5K |
| Earning Date | 01-01-0001 | 02-13-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.64 | $23.18 |
| 52 Week High | $10.45 | $123.75 |
| Indicator | EVN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 58.79 |
| Support Level | $10.63 | $79.50 |
| Resistance Level | $10.76 | $123.75 |
| Average True Range (ATR) | 0.12 | 9.63 |
| MACD | 0.01 | 0.30 |
| Stochastic Oscillator | 70.00 | 34.76 |
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.